SPIKEVAX® COVID-19 mRNA Vaccine

Resources for Canadian Healthcare Professionals and Patients

SPIKEVAX® (COVID-19 mRNA Vaccine) is indicated for active immunization against coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in individuals 6 months of age and older.

The National Advisory Committee on Immunization (NACI) strongly recommends a dose of the new formulation of COVID-19 vaccine for previously vaccinated and unvaccinated individuals at increased risk of SARS-CoV-2 infection or severe COVID-19 disease, for example: 

• All Adults 65 years of age or older

• Those 6 months of age and older who are: 

  • Residents of long-term care homes and other congregate living settings 

  • Individuals with underlying medical conditions that place them at higher risk of severe COVID-19, including children with complex health needs

  • Individuals who are pregnant 

  • Individuals in or from First Nations, Métis and Inuit communities* 

  • Members of racialized and other equity-deserving communities 

  • People who provide essential community services 

Click here for the full NACI statement on the use of COVID-19 vaccines during fall of 2024.

Please find helpful resources for SPIKEVAX below. Check back as we update with additional educational content as it becomes available. 

0.1 mg/mL Drug Identification Number (DIN): 02541270

*Autonomous decisions should be made by Indigenous Peoples with the support of healthcare and public health partners in accordance with the United Nations Declaration on the Rights of Indigenous Peoples Act.